EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae

Thomas Lavoie iD, Teresa Sierra, Katie Daffinee iD, Jason M Pogue iD, Brahim Achour, Kerry LaPlante iD

Antimicrobial Agents and Chemotherapy · 10.12.2025 · 69 (12)

DOI: 10.1128/aac.00906-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 10.12.2025. Verfasst von Thomas Lavoie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Ceftazidime, Meropenem, Enterobacter cloacae, Azabicyclo Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Melinta Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem-resistant Enterobacterales (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4 g Q8h), and ceftazidime-avibactam (2.5 g Q8h) against carbapenemase-producing (CP) (AR-1046 bla KPC-3 ) and non-CP (AR-8 bla ACT-15 ) Enterobacter cloacae isolates in a 120 h in vitro pharmacodynamic model. Additionally, we compared antimicrobial administration as a bolus or extended infusion for each isolate and treatment. For the CP strain, all treatments with meropenem-vaborbactam and ceftazidime-avibactam were bacteriostatic through 24 h. Extended-infusion meropenem-vaborbactam exhibited the most prolonged bacteriostatic activity and was significantly more effective than ceftazidime-avibactam at 120 h (0.92 log 10 lower mean colony count compared to extended-infusion ceftazidime-avibactam, P < 0.001). For the non-CP strain, all simulated treatments demonstrated initial bactericidal activity through 24 h, except for ceftazidime-avibactam bolus administration. Meropenem and meropenem-vaborbactam, administered as bolus dosing, each maintained significantly greater bacterial colony count reductions compared to extended infusion through 120 h against non-CP CRE ( P < 0.01). No significant differences were found between bolus and extended infusion for ceftazidime-avibactam ( P = 0.08). Resistance development was observed following treatment with meropenem monotherapy (minimum inhibitory concentrations increasing to >32 µg/mL for the non-CP isolate with extended infusion and to >32 µg/mL for the CP isolate with bolus and extended-infusion treatments) and ceftazidime-avibactam (minimum inhibitory concentration increase from 2 to 16 μg/mL with bolus dosing against the CP isolate). Meropenem-vaborbactam exposure did not result in the emergence of antimicrobial resistance in any of the tested models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeMeropenemEnterobacter cloacaeAzabicyclo CompoundsAnti-Bacterial AgentsCarbapenem-Resistant EnterobacteriaceaeBoronic AcidsDrug CombinationsMicrobial Sensitivity TestsHumansbeta-LactamasesBacterial ProteinsCarbapenemsEnterobacteriaceae InfectionsHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

Enterobacter cloacaeEnterobacteralescarbapenem-resistantceftazidime-avibactammeropenemmeropenem-vaborbactam

Substanzen

CeftazidimeMeropenemAzabicyclo CompoundsDrug CombinationsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationBoronic Acidsmeropenem and vaborbactambeta-Lactamasesvaborbactam

Autor:innen und Institutionen

  • Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.
  • College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
  • Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
  • Center of Innovation- Long-term Services and Supports, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.

ORCID-Profile: Thomas Lavoie, Katie Daffinee, Jason M Pogue, Kerry LaPlante

Förderung

  • Melinta Therapeutics

Zitieren

APA

Lavoie, T., Sierra, T., Daffinee, K., Pogue, J. M., Achour, B., & LaPlante, K. (2025). Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae. Antimicrobial Agents and Chemotherapy, 69(12). https://doi.org/10.1128/aac.00906-25

Vancouver

Lavoie T, Sierra T, Daffinee K, Pogue JM, Achour B, LaPlante K. Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae. Antimicrobial Agents and Chemotherapy. 2025;69(12). doi:10.1128/aac.00906-25

BibTeX
@article{Lavoie2025,
  author = {Lavoie, Thomas and Sierra, Teresa and Daffinee, Katie and Pogue, Jason M and Achour, Brahim and LaPlante, Kerry},
  title = {Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {12},
  doi = {10.1128/aac.00906-25}
}
Kostenlos starten →